Drug Trial Radar · NCT04878432
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
39
Actual
Start
Mar 17, 2022
Primary completion
Oct 26, 2023
Study completion Sep 1, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))).
Conditions
- Myelodysplastic Syndrome (MDS)
Interventions
MBG453Drug
Solution for intravenous infusion
AzacitidineDrug
Solution for subcutaneous injection or intravenous administration
DecitabineDrug
Solution for intravenous administration
INQOVI (oral decitabine)Drug
Tablet for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events and Serious Adverse EventsTime frame: Adverse events are reported from the first dose of study medication up to approximately 24 months plus 30 - 150 day safety follow up dependent on HMA, for a maximum timeframe of approximately 29 months.
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Arizona Oncology Associates
Tucson, Arizona
SCRI-Colorado Blood Cancer Institute
Denver, Colorado
Yale University School Of Medicine
New Haven, Connecticut
Advent Health Orlando
Orlando, Florida
Uni of Massachusetts Medical Center
Worcester, Massachusetts
University Of Michigan
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Tisch Hospital NYU Langone
New York, New York
Mount Sinai Medical Center
New York, New York
Duke Cancer Institute
Durham, North Carolina
University Hospitals Of Cleveland
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas
Texas Oncology San Antonio USO
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.